WASHINGTON, March 10, 2026, 10:41 EDT.
UnitedHealth Group Incorporated faces renewed scrutiny as it heads into a scheduled investor event on Tuesday, following a Wall Street Journal report that a congressional committee determined seniors shelled out roughly 10% more for Medicare Part B premiums last year. The increase stems from alleged overpayments to private Medicare Advantage plans, according to the findings. Later Tuesday, the insurer is slated to outline its strategy and go over recent performance at a Barclays healthcare conference, as detailed in a March 9 filing.
Timing is key here. With UnitedHealthcare set to represent almost one-third of 2025 Medicare Advantage plans, parent company UnitedHealth holds the top spot among private insurers. Since a January warning about an expected revenue decline in 2026—something that hasn’t happened in decades—the company’s been working to keep investors reassured. Medicare Advantage, for reference, is the privately administered branch of Medicare that serves older Americans and those with disabilities.
UnitedHealth shares lost 1.4% to $281.24 as of 10:23 a.m. EDT. Humana dropped roughly 3.2%, CVS Health slipped 1.2%, while Elevance Health managed a 1.5% gain. These names have faced selling pressure since January, after the Trump administration put forward a 0.09% bump for 2027 Medicare Advantage rates.
The Journal reported that the Joint Economic Committee was set to put out the report Tuesday. Reuters reached out to the committee for comment but got no immediate reply. The summary left insurers unnamed.
Still, UnitedHealth remains at the heart of the billing dispute. Back in January, the Senate Judiciary Committee released a report accusing the insurer of pushing hard on risk-adjustment coding in order to boost Medicare Advantage payouts—charges UnitedHealth denies. Risk adjustment, for context, is the system that increases payments to plans when their members are categorized as sicker.
UnitedHealth, in July, acknowledged it was responding to both criminal and civil inquiries from the Justice Department related to its Medicare operations. The company maintained it stands by its practices. It also pointed to CMS audits, which it said ranked its approach as one of the most accurate in the industry.
UnitedHealth’s March 9 filing noted that top executives plan to cover strategy, recent performance, market positioning, and expectations for its end markets during the Barclays event. The company already laid out a 2026 forecast: over $439 billion in revenue and adjusted earnings topping $17.75 per share. Chief Executive Stephen Hemsley, for his part, said, “finished 2025 as a much stronger company.” SEC
Some analysts remain uneasy. Back in January, James Harlow at Novare Capital Management flagged the Medicare payment proposal, saying it “starts to bring in worries about 2027 earnings growth.” Julie Utterback of Morningstar added that anyone betting on a fast rebound “may have to wait longer than hoped.” Reuters
Insurer commentary has diverged. Back in February, Humana flagged that lower Medicare star ratings—critical for bonus payouts—would drag on profit in 2026. CVS stuck to its full-year outlook, while Elevance pointed to ongoing pressure from higher medical expenses.
UnitedHealth faces a double whammy: tighter billing oversight and slim reimbursement rates could hit together. UnitedHealthcare chief Tim Noel warned back in January that if rates remain this squeezed, the company may need to make “very meaningful benefit reductions.” The 2027 rate notice isn’t set in stone until April, and the committee report wasn’t slated for release until Tuesday. Reuters
